Mode
Text Size
Log in / Sign up
Phase 3 Completed N=78 Randomized Treatment

Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer

Small Cell Lung Carcinoma
Source: ClinicalTrials.gov NCT00143455 ↗
Enrolled (actual)
78
Serious AEs
18.1%
Results posted
Jan 2010
Primary outcomePrimary: Overall Survival (OS) for the Full Analysis Population (FAP) — 10.2177; 9.6591 months — p=0.0556

Summary

To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung Cancer (ED-SCLC).

Outcome Measures

OutcomeResultp-value
PRIMARY
Overall Survival (OS) for the Full Analysis Population (FAP)
10.2177; 9.6591 0.0556
PRIMARY
Overall Survival for the Per Protocol (PP) Population
10.5791; 9.4292 0.0110 sig
SECONDARY
Number of Subjects With Overall Confirmed Response
79; 94 0.143
SECONDARY
Duration of Response (DR)
5.5195; 4.8953 0.0831
SECONDARY
Time to Tumor Progression (TTP)
5.3552; 6.2423 0.7544
SECONDARY
European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30)
SECONDARY
Tumor Related Symptoms (Pain, Dyspnea, Cough, Hemoptysis, Weight, and the Use of Opioids and Non-Opioids Analgesics)

Eligibility Criteria

Inclusion Criteria

  • Histologically or cytologically proven Small Cell Lung Cancer (SCLC)
  • WHO performance status : 0, 1

Exclusion Criteria

  • No previous radiotherapy is allowed except on bone metastases when newly diagnosed. Radiotherapy is not allowed for vena cava syndrome, a stent is recommended ;
  • No prior surgery on the primary tumor except for palliative purpose (stent for vena cava syndrome).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00143455). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search